Rosetta Genomics has won a European patent covering the use of miR-34a in the preparation of pharmaceuticals used to treat p53-negative cancers. The patent covers a core element of Rosetta's microRNA technology in the development of ...
Tags: European patent, p53-negative cancer, miR-34a, clinical technology